Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

No Significant Direct Causal Association Between TNF Pathway Biomarkers and Hip Fracture Risk: A Study Based on

Peng Xiao1, Bingqi Wei2, Guilong Zhang1

  • 1International Department of Orthopedics, Hospital of Chengdu University of Traditional Chinese Medicine.

Journal of Visualized Experiments : Jove
|June 22, 2026
PubMed
Summary

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Mediating Role of Functional Limitations Between Recurrent Falls and Knee Osteoarthritis: An Observational Study Based on CHARLS 2015.

Journal of visualized experiments : JoVE·2026
Same author

A novel Au-Se nanoplatform for co-delivery of cGAMP and acriflavine synergizes with photothermal therapy to enhance anti-tumor immunity via STING activation and HIF-1α inhibition.

Journal of nanobiotechnology·2026
Same author

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a bibliometric analysis of global research trends and research hotspots from 2006 to 2025.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Hydrogen peroxide self-supplied nanozyme system for synergistic prostate cancer therapy via ferroptosis/pyroptosis and Ca<sup>2+</sup> overload-induced apoptosis.

Journal of nanobiotechnology·2026
Same author

Climate Change Accelerates Nitrate Delivery to Groundwater.

Environmental science & technology·2026
Same author

The impact of nursing interns' intolerance of uncertainty on professional identity: the mediating role of career resilience.

Frontiers in medicine·2026
This summary is machine-generated.

This study found no link between TNF inhibitors and hip fractures using pharmacovigilance data. Mendelian randomization also showed no direct causal relationship between TNF pathway biomarkers and hip fracture risk.

Area of Science:

  • Gerontology
  • Immunology
  • Pharmacovigilance

Background:

  • Hip fractures are a significant health concern in the elderly.
  • Altered tumor necrosis factor-alpha (TNF-α) signaling is often observed in elderly individuals with hip fractures.
  • The role of TNF pathway biomarkers in hip fracture risk remains under-explored.

Purpose of the Study:

  • To investigate the association between TNF inhibitor exposure and hip fracture risk.
  • To explore the causal relationship between TNF pathway biomarkers and hip fracture.
  • To determine if TNF pathway biomarkers are independent determinants of hip fracture risk.

Main Methods:

  • Pharmacovigilance data from 2014-2023 for five TNF inhibitors were analyzed using four disproportionality methods.

Related Experiment Videos

  • Mendelian randomization analyses were performed using TNF-α, sTNFR1, and sTNFR2 as exposures and hip fracture as the outcome.
  • Data standardization, cleaning, and complementary analyses were conducted.

    • Main Results:

    • Pharmacovigilance analyses did not reveal a significant association between TNF inhibitor use and hip fracture-related adverse events.
    • Mendelian randomization studies found no significant direct causal link between genetically predicted TNF-α, sTNFR1, or sTNFR2 and hip fracture risk.
    • Consistent results were observed across all applied analytical methods.

    Conclusions:

    • TNF pathway biomarkers are unlikely to be independent direct determinants of hip fracture risk.
    • These findings may inform future research into hip fracture mechanisms and prevention strategies.
    • Further mechanistic studies are warranted to fully understand the interplay between TNF signaling and bone health.